



**Michael Schlander, Oliver Schwarz,
and Ramon Schaefer:**

**An Update on the Economic Value
of a Statistical Life Year in Europe**



Session OS 27 Economic Evaluation and Decision Making (B) – Tuesday, June 20, 2017 – 16:30 – 18:00



1. Background & Research Question
2. Material & Methods
3. Results
 - ↪ European Studies
 - ↪ [Global Studies]
 - ↪ Heterogeneity, Methods and Regions
 - ↪ Summary of Results
4. Conclusions



1

Background & Research Question



Copyrighted Material
Frank Ackerman & Lisa Heinzerling

Health Economics

Willingness to Pay for a Quality-adjusted Life Year:

In Search of a Standard

RICHARD A. HIRTH, PhD, MICHAEL E. CHERNEW
EDWARD MILLER, MA, A. MARK FENDRICK, M
WILLIAM G. WEISSERT, PhD

Janusz R. Mrozek
Laura O. Taylor

COLLECTION REVIEW

A Systematic Review of Studies Eliciting Willingness-to-Pay per Quality-Adjusted Life Year: Does It Justify CE Threshold?

Khachapon Nimdet¹, Nathorn Chaiyakunapruk^{2,3,4,5*}, Kittaya Vichansavakul¹,
Surachat Ngorsuraches¹

What Determines
the Value of Life?
A Meta-Analysis

PRICELESS

On Knowing the Price of Everything
and the Value of Nothing

"A damning indictment of cost-benefit analysis applied to health
and environmental protection." —Robert F. Kennedy Jr.
Copyrighted Material



Benchmarks for Cost Effectiveness

→ Examples of international *de facto* benchmarks:

- **New Zealand** (PHARMAC):
NZ-\$ 20,000 / QALY¹
- **Australia** (PBAC):
AUS-\$ 42,000 / LYG to AUS-\$ 76,000 / LYG²
- **England and Wales** (NICE):
£ 20,000 – £ 30,000 / QALY
- **United States** (some MCOs):
US-\$ 50,000 – US-\$ 100,000 / QALY³
- **Canada** (proposed “grades of recommendation”):
CAN-\$ 20,000 – CAN-\$ 100,000 / QALY⁴
- **WHO** (recommendation): 1-3 times GDP/capita / DALY⁵

→ **No scientific basis**

¹C. Pritchard (2002); QALY: “quality-adjusted life year”; ²George et al. (2001); LYG: “life year gained”

³D.M. Cutler, M. McClellan (2001); ⁴A. Laupacis et al. (1992); ⁵DALY: “disability-adjusted life year”



In Search of a Scientific Basis

– Demand-Side Analyses

- **Health Care Programs (or Interventions):**
social (or individual) WTP, holistic
- **Attributes of Health Care Programs (or Interventions):**
social (or individual) WTP, characteristics (and their interaction)
- **Quality-Adjusted Life Years (Individual or Social WTP-Q):**
QALY maximization hypothesis; constant proportional trade-off...

– Supply-Side Analyses

- **PROs and Efficiency Frontier Approach (e.g., IQWiG):**
flexible benchmarks, contingent on therapeutic area
and rationality of prior pricing and reimbursement decisions
- **Quality-Adjusted Life Years (Shadow Prices, e.g., York):**
universal benchmark, (in addition to assumptions above)
also contingent on rationality of health care budget



Answers Offered by [Health] Economists

– Value of a Statistical Life Year (VSLY)


- **Human Capital Approach:**
resting on productivity, *rejected by modern welfare economics*
- **Revealed Preferences Approach:**
observed human behavior (job risk or non-occupational safety)
- **Stated Preferences Approach:** direct elicitation of preferences
 - **contingent valuation (CV):** direct or referendum style questions
 - **discrete choice experiments (DCEs):** choice alternatives, where the different goods or programs are defined by their attributes

– Willingness-to-Pay for a QALY (WTP-Q)

- With adjustment for reduced average quality of life in later years, WTP-Q may be ~10% greater than VSLY (Hirth et al., 2000)
- WTP-Q exists only if QALY maximization hypothesis is accepted and normative and empirical grounds for concern are disregarded



In Search of a Standard (Hirth et al., 2000¹)



¹R. Hirth et al. (2000): median based on 35 estimates based on WTP approaches, US-\$ (1997) 265,345.

A total of 37 studies (28 of which came from the U.S.) yielded 42 VSL estimates suitable for inclusion in the analysis.



Research Questions

- **Demand-Side Perspective:** What Can We Learn About the Economic Value of a Statistical Life Year (“VSLY”) from Empirical Studies Reporting Original Data on the Value of a Statistical Life (“VSL”) over the Last Two Decades (1995-2015)?
 - Methodology of empirical studies over the last two decades
 - Heterogeneity of estimates, by method and by area of origin
 - No adjustment for health-related quality of life;
no attempt to derive WTP-Q estimates from VSLY estimates
 - No specific review of the Quality-Adjusted Life Year literature
- **Two levels of analysis**
 - **European data**
 - Worldwide data



2

Materials & Methods



Systematic Literature Search

Databases:

EconBiz and EconLit (German and English); January 1995 – December 2015

Supplementary search in published reviews and meta-analyses

Search Terms:

Value of Life, Statistical Life, Value of a Statistical Life, Value of a Life Year,
Value of a Statistical Life Year, Value of a Quality-Adjusted Life Year (QALY)

VSL Estimates:

After elimination of duplicates, extracting the reported value of (a statistical) life (VSL) for each experimental setting studied,

using the base case VSL if reported by the authors; otherwise calculating the mean VSL when various methods were employed on the same dataset




Study Eligibility Criteria

- **Report VSL(Y) based on an original data analysis**
 - Reports clearly state currency and year of VSL(Y) estimates
 - No reviews or meta-analyses
 - No specific review of WTP-Q (“value of a QALY”) literature
- **Data sources and methods used specified**
 - HC; SP/CV; SP/DCE; RP and type of risk (WR, non-occupational)
 - Characteristics of study population (time of survey; respondent selection criteria, age, male/female; white/blue collar, ...)
 - Identification of national origin of data
- **European subset**
 - Data originating from a European setting




Literature Search: European Studies





Literature Search: Global Results





Extracting Data from Study Reports

Data extracted for analysis included the following:

- VSL (base case or mean, and range, for each experimental setting)
- Country and Year (for origin of data and for publication)
- Method: HC; WTP: SP (CV / DCE), RP (WR / non-occupational safety); cross-sectional / longitudinal / panel data analysis
- Population studied (size; blue-collar / white-collar; male/female ratio)
- Mean age of study population
- Type of risk / risk reduction / fatality risk (mean, min/max)
- Currency (and year); average annual income

Additional data sources used for analysis:

- Life expectancy (by year, sex, and age): WHO Life Tables
- GDP / capita (by year): World Bank
- CPI, PPPs, exchange rates: World Bank



Computing the VSLY from Reported VSL Data

Abbreviated calculation procedures:

- VSL (base case or mean for each experimental setting) from study
- Currency reconversion from US-\$ (or else) to LCU (exchange rates)
- VSL inflated to year 2014 using country-specific CPIs
- GDP / capita from year of data generation, inflated as VSL
- Conversion of LCU values for 2014 to Euro (PPPs)

VSLY computation:

- Calculation separately for men and women,
Residual Life Expectancy data from WHO Life Tables by Country
- Base case discount rate 3% (for sensitivity analyses, 0% - 10%)
- Formulas: $VSLY = \frac{VSL \cdot (1+r)^{t-1} \cdot r}{(1+r)^t - 1}$ or (for $r = 0\%$): $VSLY = \frac{VSL}{t}$
- Calculating VSLY average (and range, if data were available),
weighted by study population sex ratio



Database for Analysis

→ **European data:**

→ **41 studies,**

yielding a total of 49 unique VSL estimates

→ **Regional origin of studies yielding VSL estimates:**

Sweden (13),

United Kingdom (4);

France, Germany, Norway, Switzerland (3 each);

Italy, Netherlands (2 each);

Austria, Czech Republic, Denmark, Netherlands, Poland (1 each);

plus three comparative international studies

(reporting VSL for more than one country each)

→ **Methodological basis of estimates:**

HC, 0; RP/WR, 11; SP/DCE, 11; SP/CV, 27



3

Results

- ↪ European Studies
- ↪ [Global Studies]
- ↪ Heterogeneity, Methods and Regions
- ↪ Summary of Results



Overall European Results:

Mean and Median VSL and VSLY


	Mean	95% Confidence Intervals (nonparametric bootstraps)	
		Lower Bound	Upper bound
VSL	€ 4,721,286	€ 2,940,381	€ 6,502,190
VSLY	€ 209,424	€ 127,307	€ 291,540

	Median	95% Confidence Intervals (nonparametric bootstraps)	
		Lower Bound	Upper bound
VSL	€ 3,428,516	€ 2,727,662	€ 4,129,370
VSLY	€ 158,448	€ 136,147	€ 180,750



European Results


Median VSL Estimates by Method





European Results

Median VSLY Estimates by Method





European Results

Revealed Preference Studies (Wage Risk)

	Mean	Median	25% Percentile	75% Percentile
All RP/WR Studies				
VSL	€ 8,436,298	€ 5,319,627	€ 2,192,626	€ 7,340,022
VSLY	€ 376,493	€ 231,422	€ 100,058	€ 334,954



European Results


Revealed Preference Studies (Wage Risk)

	Mean	Median	25% Percentile	75% Percentile
All RP/WR Studies				
VSLY	€ 376,493	€ 231,422	€ 100,058	€ 334,954
Scenario Analysis (1): RP/WR-Studies, <i>excluding Spengler (2004) and Schaffner and Spengler (2005)</i>				
VSLY	€ 491,550	€ 255,023	€ 100,058	€ 347,818
Scenario Analysis (2): like Scenario (1), <i>excluding Sandy and Elliott (1996)</i>				
VSLY	€ 214,642	€ 243,222	€ 100,058	€ 334,954



European Results

Revealed Preference Studies (Wage Risk)





European Results


Stated Preference Studies (CV, DCE)

	Mean	Median	25% Percentile	75% Percentile
VSL (CV)	€ 3,311,944	€ 2,978,677	€ 2,319,086	€ 3,942,348
VSLY (CV)	€ 147,053	€ 137,413	€ 98,268	€ 164,409
VSL (DCE)	€ 4,465,568	€ 4,603,748	€ 2,169,577	€ 6,782,770
VSLY (DCE)	€ 195,448	€ 187,857	€ 102,472	€ 296,563



European Results


Stated Preference Studies (CV)





European Results

Stated Preference Studies (DCE)






European Results

Panel vs. Cross-Sectional Analysis

	Mean	Median	25% Percentile	75% Percentile
<i>cross-sectional analysis</i>	€ 213,676	€ 158,753	€ 99,125	€ 204,121
<i>panel data analysis</i>	€ 183,913	€ 143,614	€ 100,058	€ 296,563




Panel vs. Cross-Sectional Analysis



excludes outside values




European Results





European Results





European Results

Median VSL / VSLY by Region

	Mean	Median	25% Percentile	75% Percentile
Continental Europe				
VSL	€ 3,831,291	€ 3,235,183	€ 2,192,626	€ 5,319,627
VSLY	€ 170,241	€ 158,448	€ 94,601	€ 231,422
United Kingdom				
VSL	€ 10,273,115	€ 2,244,332	€ 1,964,914	€ 5,848,654
VSLY	€ 469,957	€ 117,956	€ 102,472	€ 255,023
Northern Europe (including Denmark)				
VSL	€ 4,106,781	€ 3,754,427	€ 2,978,677	€ 4,197,741
VSLY	€ 177,000	€ 161,052	€ 124,020	€ 189,478



European Results

VSLY / GDP/capita (by region)

Continental
Europe


EU

Northern
Europe

NC

United
Kingdom

UK






European Results

VSLY / GDP/capita (by region)				
	Mean	Median	25% Percentile	75% Percentile
Continental Europe	5.74	4.75	2.66	7.56
Northern Europe	5.92	5.79	4.04	6.43
United Kingdom	26.00	4.51	3.32	8.67
Europe (overall)	8.29	5.10	3.37	7.01



European Results

VSLY / GDP/capita (by method: RP vs. SP)





European Results


VSLY / GDP/capita (by method: c-s vs. panel)

cross-
sectional
analysis

cross

panel
data
analysis

panel



excludes outside values



European Results

VSLY / GDP/capita (by method)

	Mean	Median	25% Percentile	75% Percentile
Revealed Preferences	18.82	8.67	3.25	10.87
Stated Preferences	5.24	5.09	3.37	6.39


	Mean	Median	25% Percentile	75% Percentile
<i>cross-sectional</i>	8.71	5.15	3.65	6.62
<i>panel data</i>	5.73	4.66	3.25	8.67



European Results

Sensitivity Analysis (VSLY)

Combined Impact of Discount Rate and Uncertainty





European Results

Sensitivity Analysis (VSLY)

Combined Impact of Discount Rate and Uncertainty

	Discount Rate				
	1%	2%	3%	4%	5%
25% Percentile	76,340	87,808	100,058	115,935	130,039
Median	117,431	139,552	158,448	182,008	206,114
75% Percentile	169,235	199,136	231,422	265,792	301,918



4

Summary and Conclusions



Current European Analysis (1995-2015)

compared with

US-Driven International Analysis (<1997)

VSLY		Indirect Measurement		Direct Measurement	
Method					
Study	HC	RP-WR	RP-S	SP-CV	SP-DCE
Schlender et al. (2017): 1995-2015	n.a.	€ 231,422	n.a.	€ 137,413	€ 187,857
Hirth et al. (2000): 1969-1997	€ 25,950	€ 448,500	€ 97,800	€ 168,900	n.a.



Summary – Europe

- Database: 41 studies, yielding 49 unique European estimates
- Median VSLY = 158,448 € [2014]
- 95% confidence interval, 136,147 € - 180,750 €
(nonparametric bootstrapping)
- Median VSLY = 5.10 times GDP / capita
- WTP-Q > VSLY (transformation factor reportedly around ~1.1)
- Large heterogeneity between studies, which in part may be explained by different methodological approaches and by different regional sources of data (significant in the worldwide dataset only)
- Nevertheless, VSLY >> currently accepted benchmarks for cost effectiveness (among health economists and the HTA community)



Implications

Currently used benchmarks for cost effectiveness (WTP-Q) appear to be much lower than empirical willingness-to-pay for a life year (or “VSLY”) in other sectors of life.

However:

- Policy implications will be influenced by the type of health care system in question; an NHS with a politically determined health budget may respond differently than a bottom-up financed system.
- We have no intention to suggest a new benchmark for WTP-Q.
- Among other concerns, there are data which suggest that the conversion of length and quality of life, as it is inherent in the conventional QALY model, may be flawed.
- We believe there are compelling reasons to reject a universal WTP-Q benchmark on both normative and empirical grounds.



Thank You for Your Attention!

Professor **Michael Schlander**, M.D., Ph.D., M.B.A.

Contact

www.innoval-hc.com

www.michaelschlander.com

michael.schlander@dkfz.de

michael.schlander@innoval-hc.com

INNOVAL^{HC}
Institute for Innovation & Valuation
in Health Care

Deutsches Krebsforschungszentrum (DKFZ)

Im Neuenheimer Feld 581 (TP4)

D-69120 Heidelberg

Phone: +49 (0) 6221 42 1910

InnoVal^{HC}

An der Ringkirche 4

D-65197 Wiesbaden

+49 (0) 611 4080 7890